Drug pricing
Featured Topics
Lead story
Other featured articles
-
The Cantwell-Grassley PBM Bill Is Much Needed But More Can Be Done
The proposed reforms are a helpful start, but could go further in addressing the lack of competition in the U.S. PBM market.
Posted in -
Drugmakers Aren’t Driving Inflation
Drug prices have not experienced the major rise in cost like eggs or gasoline, and instituting price controls on drugs would only stifle medical innovation.
Posted in -
PBMs Are Inflating the Cost of Generic Drugs. They Must Be Reined In
Anti-competitive practices and a lack of transparency in the generic drug market allow pharmacy benefit managers to profit off patients and payers.
Posted in -
The FDA Could Do More to Promote Generic Competition: Here’s How
USC-Brookings Schaeffer Initiative experts focus on three areas of FDA authority that could be refined to better promote generic competition: the Citizen Petition mechanism; the approval of so-called complex generic drugs; and the phenomenon known as “parking” under the Hatch-Waxman Act.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug pricing
Our Work In Drug pricing
-
Schaeffer White Paper Highlights Failures in Generic Drug Market That Cost Patients
A new USC Schaeffer Center paper highlights tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, that are costing patients, employers and the government billions for what should be inexpensive medicines.
Categorized in -
U.S. Consumers Overpay for Generic Drugs
Tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, are costing patients, employers and the government billions for what should be inexpensive medicines.
Categorized in -
Comments to the Federal Trade Commission on Pharmacy Benefit Managers
Researchers at the USC Schaeffer Center have been studying the pharmaceutical distribution system since 2016; these comments about PBMs draw on that body of research.
Categorized in -
Messages in Prescription Drug Advertising for Four Chronic Diseases, 2003-2016: A Content Analysis
Examining the frequency and content of messages related to pharmacological and evidence-based, non-pharmaceutical treatments in direct-to-consumer advertising (DTCA) for prescription drugs treating four chronic diseases in the United States.
Categorized in -
Who Is Really Driving Up Insulin Costs?
In the long term, capping insulin payments at $35 a month is just shuffling the deck rather than changing the game of insulin costs.
Categorized in -
Pharmacy Switching in Response to Preferred Pharmacy Networks in Medicare Part D
Researchers evaluate the effects of preferred pharmacy networks—a tool that Medicare Part D plans have recently adopted to steer patients to lower cost pharmacies—on the use of preferred pharmacies and factors underlying beneficiaries’ decisions on whether to switch to preferred pharmacies.
Categorized in